PellePharm Sells Minority Equity Stake to LEO Pharma

Represented PellePharm, a developer of skin cancer therapeutics intended to mitigate the tumor burden with basal cell carcinomas, in the sale of a minority equity stake and an option to acquire the remainder of its equity, to LEO Pharma.  

*prior firm experience